Iruxol N

Collagenase Clostridium Histolyticum, the active ingredient in Iruxol N, is an enzyme (collagenase) presented as a cutaneous formulation for topical use. It is employed to debride necrotic tissue in chronic wounds, pressure ulcers and diabetic foot ulcers.

GNH USA supplies Iruxol N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iruxol N, an enzymatic debridement agent, is used in wound care to remove necrotic tissue and improve healing. - Pressure ulcers: facilitates removal of necrotic tissue and promotes granulation tissue formation. - Diabetic foot ulcers: aids debridement of chronic lesions, supporting faster wound closure. - Chronic non‑healing wounds: enzymatically clears extracellular matrix debris to improve the wound bed.

Local and systemic reactions may occur with Iruxol N; reported events are categorized by frequency.

Common Side Effects: - Local pain or burning sensation at the application site. - Redness or erythema around the treated area. - Swelling or edema of the surrounding skin. - Mild itching or pruritus. - Slight bleeding or oozing from the debrided tissue. - Increased wound drainage.

Serious or Rare Side Effects: - Allergic reaction including anaphylaxis. - Severe infection of the treated wound. - Unintended tissue necrosis extending beyond target area. - Systemic hypersensitivity responses. - Significant hemorrhage. - Deep ulceration or perforation.

Iruxol N should be used under professional supervision with attention to wound characteristics and patient safety. - Assess wound type: ensure the wound contains necrotic tissue suitable for enzymatic debridement. - Avoid application on healthy or granulating tissue. - Monitor for signs of infection or excessive pain during treatment. - Do not combine with other topical proteolytic enzymes unless directed by a clinician. - Use only as prescribed by a qualified healthcare provider. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Iruxol N may interact with other topical agents or systemic medications that affect coagulation or wound healing.

Major Interactions (Avoid): - Concurrent use of other proteolytic enzymes, which can amplify tissue breakdown. - Systemic anticoagulants (e.g., warfarin, heparin) increasing bleeding risk at the application site. - Topical antibiotics containing oxidizing agents that may inactivate the collagenase.

Moderate Interactions (Monitor Closely): - Moisturizers or dressings containing zinc oxide or high protein content that could bind the enzyme. - Radiation therapy applied to the same wound area, potentially altering enzyme activity. - Use with corticosteroid creams, which may reduce local inflammatory response and affect efficacy. - Application over areas treated with chemical cautery or laser therapy.